ReviewImmunity, inflammation and disease2023
Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: A review.
Review in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Determinants of Malaria Vaccine Acceptance: A Systematic Review and Meta-Analysis of Awareness, Acceptance, Hesitancy, and Willingness to Pay.Immunity, inflammation and disease · 2025Pooled it
- Determinants of caregivers' acceptance of the malaria vaccine: The case of Bamenda and Bamenda III Health Districts in Cameroon.Public health in practice (Oxford, England) · 2026Article
- Public health impact of catch-up vaccination or additional booster doses with pre-erythrocytic malaria vaccine R21/Matrix-M: a modelling study.BMC medicine · 2026Article
- Healthcare workers' beliefs, readiness, and acceptance of malaria vaccine in Southwest Nigeria: addressing misconceptions and uptake barriers.Malaria journal · 2026Review
- Determinants of Malaria Vaccine Awareness Among Women in Ghana: Findings From the 2022 Ghana Malaria Indicator Survey.Public health challenges · 2025Article
- Physicians' knowledge of, and willingness to encourage caregivers to partake in the RTS S/AS01 and R21 matrix M malaria vaccines roll out - a national survey in Nigeria.BMC infectious diseases · 2025Article
- General knowledge and attitude of healthcare professionals and infrastructural readiness prior to implementation of malaria vaccine in selected hospitals in Tororo district, Uganda: a cross-sectional study.BMC public health · 2025Article
- Malaria Vaccines and Global Equity: A Scoping Review of Current Progress and Future Directions.Biomedicines · 2025Review
- Current update on malaria in pregnancy: a systematic review.Tropical diseases, travel medicine and vaccines · 2025Review
- China's Malaria R&D Innovations: A Scoping Review from 2013-2023.China CDC weekly · 2025Article
- Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication.Ethiopian journal of health sciences · 2025Review
- Acceptance and affordability of malaria vaccines: issues relating to hesitancy and willingness to pay amongst Nigerian parents of under-five children.Malaria journal · 2025Article
- Knowledge and willingness towards malaria vaccines among caregivers in Dar es Salaam, Tanzania.Malaria journal · 2025Article
- Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions.Clinical pharmacology : advances and applications · 2025Review
- Community-level determinants of RTS,S/AS01 vaccine acceptance in a hyperendemic Ghanaian Region: A Bayesian multilevel analysis from Kpando Municipality, Ghana.PLOS global public health · 2025Article
- Intra-lymph node crosslinking of antigen-bearing polymers enhances humoral immunity and dendritic cell activation.Bioengineering & translational medicine · 2024Article
- Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies.Infection · 2024Article
- Hesitancy towards R21/Matrix-M malaria vaccine among Ghanaian parents and attitudes towards immunizing non-eligible children: a cross-sectional survey.Malaria journal · 2024Article
- Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation.BMJ global health · 2024Review
- Breaking the malaria barrier: the WHO-approved R21/Matrix-M vaccine and its global impact - an editorial.Annals of medicine and surgery (2012) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn malaria-stricken regions, malaria continues to be one of the primary causes of mortality for children. The number of malaria-related fatalities has drastically decreased because of artemisinin-based pharmacological regimens.
methodsTwo independent researchers did a comprehensive literature search using PubMed/MEDLINE and Google Scholar from its inception to September 2022.
resultsAfter evaluating RTS, S/AS01 for its safety, effectiveness, and feasibility, the European Medicines Agency (EMA) issued a favorable conclusion. It was suggested that the RTS, S malaria vaccine be used extensively by the World Health Organization on October 6, 2021. The successful pilot program testing the malaria vaccine in Ghana, Kenya, and Malawi served as the basis for this proposal.
conclusionSeveral challenges need to be addressed to ensure the success of vaccination programs. From the acceptability perspective, issues such as inadequate community engagement, concerns about side effects, and issues with the delivery and quality of healthcare services can affect the acceptance of the vaccine. From the feasibility standpoint, factors such as lack of transportation or long distances to healthcare facilities and the perception of completion of the vaccination calendar can affect the feasibility of the vaccine. Lastly, the availability of the vaccine is also a major concern as it may not be readily available to meet the demands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.